Retina Center of Texas | Southlake, TX

Research site

(Unclaimed)

Location

305 Morrison Park Drive Suite 100, Southlake, Texas, United States of America

Site insights

Top conditions

Top treatments

Faricimab

Ranibizumab

UBX1325

IONIS-FB-LRx

Avacincaptad pegol

Zimura

AU-011

Axitinib

THR-687

Foselutoclax

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 17 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting

Diabetic Retinopathy

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling

Indeterminate Lesions

Ocular Melanoma

Device: Suprachoroidal Microinjector

Drug: Bel-sar

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atroph...

Enrolling

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Drug: Placebo

Drug: Pozelimab

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Active, not recruiting

Diabetic Macular Edema

Drug: Faricimab

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting

Edema

Diabetic Macular Edema

Drug: foselutoclax

Drug: Aflibercept

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (BURGUNDY)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling

Macular Degeneration

Drug: Ranibizumab

Drug: Zifibancimig